Vistara NIPT Single Gene Test | Natera

Vistara

Most comprehensive prenatal single-gene screening test

Vistara identifies risk for single-gene disorders that may have otherwise gone undetected prenatally

Tests For:

25 serious genetic conditions

Collection Sample:

Blood draw

Turn Around Time:

2-3 weeks


Vistara screens cell-free DNA (cfDNA) for serious genetic conditions that affect quality of life and may benefit from medical and/or surgical intervention.


Screened conditions include:

  • Noonan syndrome
  • Achondroplasia
  • Osteogenesis imperfecta
  • Rett syndrome
  • And 21 other single-gene disorders across 30 genes

See all conditions

Conditions screened by Vistara have a combined incidence of 1 in 600 – higher than that of Down syndrome.


Vistara has a combined analytical sensitivity and specificity of >99% in validation studies and no known false positives in commercial experience.

 

Vistara identifies risk for single-gene disorders that may have otherwise gone undetected prenatally.

  • Ultrasound findings are not a reliable indicator.
  • Conditions are not detected with standard karyotype or microarray analysis.
  • Family history is typically not a good indicator of risk (often de novo).
  • Early identification of these conditions is clinically actionable.

Vistara prenatal screening can lead to improved delivery and targeted neonatal care.


Noonan
syndrome

Clinical actions

  • Fetal echocardiogram
  • Labor and delivery management
  • Early assessment for learning differences

Achondroplasia
 

Clinical actions

  • Labor and delivery management
  • Monitor for spinal stenosis
  • Early sleep studies to reduce risk of SIDS

Osteogenesis imperfecta

Clinical actions

  • Labor and delivery management to avoid fractures
  • Neonatal care
  • Early recognition and treatment of fractures

Consider Vistara for the following indications: